Laser Treatments in Dermatology: Types and Clinical Indications

Laser technology represents one of the most precisely engineered tool sets in clinical dermatology, enabling targeted tissue modification at depths and wavelengths that scalpels and topical agents cannot replicate. This page covers the principal laser categories used in dermatologic practice, the optical and thermal mechanisms that govern their effects, the clinical indications and contraindications that define appropriate use, and the regulatory and safety frameworks that govern device deployment in the United States. Understanding these parameters helps patients and researchers interpret treatment protocols accurately and situate laser therapies within the broader landscape of dermatologic care.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

A medical laser is a device that emits a coherent, monochromatic, collimated beam of light at a specific wavelength. In dermatology, the clinical utility of a laser depends almost entirely on wavelength selectivity — the capacity to deposit energy into a defined target chromophore (melanin, oxyhemoglobin, water, or exogenous pigment) while sparing surrounding tissue.

The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) classifies laser devices under 21 CFR Part 892 (radiology devices) and Part 878 (general and plastic surgery devices), depending on the intended use. FDA 510(k) clearance or Premarket Approval (PMA) is required before a laser system can be marketed for a specific dermatologic indication (FDA CDRH Device Database).

Laser-based interventions in dermatology span two broad operational categories: ablative procedures that vaporize or remove tissue layers, and non-ablative procedures that heat targets without disrupting the epidermal surface. A third operational mode — fractional delivery — subdivides the beam into microscopic treatment zones, leaving intervening tissue intact to accelerate healing. These categories are not marketing designations; they correspond to measurable differences in tissue temperature, depth of penetration, and recovery timelines.

The scope of dermatologic laser indications, as documented in American Academy of Dermatology (AAD) clinical practice guidelines, includes vascular lesions, pigmented lesions, hair removal, tattoo removal, skin resurfacing, acne scarring, and onychomycosis, among other conditions.

Core mechanics or structure

The foundational principle governing laser-tissue interaction is selective photothermolysis, articulated by Anderson and Parrish in a 1983 Science paper. The principle holds that if a wavelength is preferentially absorbed by a target chromophore, and if the pulse duration is shorter than or equal to the target's thermal relaxation time (TRT), thermal damage remains confined to that target.

Three parameters define every clinical laser interaction:

1. Wavelength (nm): Determines chromophore selectivity. Melanin absorbs broadly from 250 nm to 1200 nm, with peak absorption in the UV-visible range. Oxyhemoglobin absorption peaks occur near 418 nm, 542 nm, and 577 nm. Water absorbs strongly above 1300 nm, making mid-infrared lasers effective resurfacing tools.

2. Pulse duration: Measured in milliseconds (ms), microseconds (μs), or nanoseconds (ns). Shorter pulses confine heat within smaller targets. Picosecond-domain pulses (10⁻¹² seconds) fragment tattoo ink particles more efficiently than nanosecond Q-switched devices by generating photoacoustic as well as photothermal effects.

3. Fluence (J/cm²): The energy density delivered per unit area. Insufficient fluence produces subtherapeutic effect; excessive fluence causes nonselective thermal injury and scarring.

These three variables interact. A 755 nm alexandrite laser at 3 ms pulse duration and 20 J/cm² fluence behaves clinically very differently from the same wavelength at 50 ns — the former is optimized for hair follicle destruction, the latter for melanin-rich pigmented lesions.

Causal relationships or drivers

The adoption and diversification of laser modalities in dermatology are driven by three overlapping factors: chromophore physics, device engineering, and clinical demand shaped by condition prevalence.

Chromophore physics establishes hard limits. Tattoo ink particles, for example, are typically 40–300 nm in diameter and are phagocytized by dermal macrophages. Their TRT is in the nanosecond-to-picosecond range. Only laser pulses shorter than approximately 100 ns can selectively rupture particles without scorching surrounding dermis — a physical constraint that explains why continuous-wave lasers are ineffective for tattoo removal.

Device engineering has produced wavelength-specific platforms: Nd:YAG lasers at 1064 nm and 532 nm, diode lasers at 800–980 nm, CO₂ lasers at 10,600 nm, Er:YAG lasers at 2940 nm, pulsed dye lasers (PDL) at 585–595 nm, alexandrite lasers at 755 nm, and ruby lasers at 694 nm. Each platform originated from a specific clinical need and chromophore target.

Condition prevalence drives clinical volumes. Acne affects approximately 50 million Americans annually, according to the American Academy of Dermatology (AAD Statistics), generating substantial demand for laser-based acne scar management. Skin cancer, diagnosed in more than 5 million Americans per year (AAD), drives demand for resurfacing procedures that address field-change and actinic damage. The intersection of these conditions with cosmetic vs. medical dermatology questions shapes both insurance coverage determinations and device market development.

Classification boundaries

Dermatologic lasers are most usefully classified along two axes: wavelength domain (visible, near-infrared, mid-infrared) and tissue interaction mode (ablative, non-ablative, fractional).

Pulsed Dye Laser (PDL) — 585/595 nm: Targets oxyhemoglobin. Primary indications: port wine stains, hemangiomas, telangiectasias, hypertrophic scars, and psoriatic plaques. Non-ablative at standard fluences.

Q-Switched Nd:YAG — 1064 nm / 532 nm: Targets melanin and tattoo pigments. At 1064 nm, reaches deeper dermal melanin with less epidermal absorption — preferred for darker Fitzpatrick phototypes (IV–VI). At 532 nm, targets superficial pigment and red-spectrum tattoo inks.

Alexandrite — 755 nm: Strong melanin absorption. Indications: hair removal, pigmented lesions, tattoo removal (especially blue-black inks). Carries higher risk of dyspigmentation in darker skin types.

Diode — 800–980 nm: Targets melanin in hair follicles with lower epidermal melanin absorption than alexandrite. Commonly used for hair removal across a wider range of Fitzpatrick types.

CO₂ — 10,600 nm: Water is the primary chromophore. Ablative resurfacing for actinic keratoses, rhytides, scars, and sebaceous hyperplasia. Fractional CO₂ reduces downtime from 2–4 weeks (full ablative) to approximately 5–10 days.

Er:YAG — 2940 nm: Water absorption coefficient approximately 12–18 times higher than CO₂, producing shallower ablation with less residual thermal damage. Less hemostasis than CO₂; faster healing.

Picosecond Lasers (755 nm, 532 nm, 1064 nm): Generate pulses in the 300–750 picosecond range. FDA clearances exist for tattoo removal and pigmented lesion treatment. Photoacoustic mechanism produces superior ink fragmentation with lower fluence compared to nanosecond Q-switched devices.

Tradeoffs and tensions

No single laser platform suits all indications or all patients. The primary tensions in clinical laser selection involve Fitzpatrick phototype safety, depth-versus-selectivity tradeoffs, and the balance between efficacy and recovery burden.

Fitzpatrick Phototype and Dyspigmentation Risk: The Fitzpatrick scale (NIH MedlinePlus) stratifies skin from Type I (always burns, never tans) to Type VI (never burns, deeply pigmented). Shorter visible wavelengths that are highly efficient in Types I–III carry disproportionate epidermal melanin absorption risk in Types IV–VI, creating competitive absorption that can cause post-inflammatory hyperpigmentation (PIH) or permanent hypopigmentation. Longer wavelengths (1064 nm Nd:YAG) are generally preferred for darker phototypes.

Ablative Efficacy vs. Recovery: Full ablative CO₂ resurfacing produces the most dramatic improvement in rhytides and photodamage of any laser procedure but requires 2–4 weeks of wound care and carries risk of prolonged erythema lasting up to 6 months. Fractional approaches reduce downtime but require multiple treatment sessions — typically 3–6 — to approximate comparable cumulative effect. Patients with limited recovery time face a direct tradeoff between single-session efficacy and multi-session convenience.

Tattoo Ink Variability: No regulatory body mandates standardized formulation of tattoo pigments. The FDA has noted that tattoo ink formulations vary substantially in particle size, composition, and density (FDA Tattoo Safety). This variability makes laser response unpredictable; yellow and fluorescent inks absorb poorly across all available wavelengths, remaining among the most treatment-resistant pigment colors.

The regulatory context for dermatology provides additional detail on how FDA device clearance categories and state medical board scope-of-practice rules intersect with laser procedure delivery.

Common misconceptions

Misconception: Laser hair removal is permanent after one session.
Correction: FDA clearance language for hair removal lasers uses the term "permanent hair reduction," not elimination. Hair follicles in the anagen (active growth) phase are selectively targeted; follicles in telogen or catagen phases are not adequately treated. Clinical protocols require 6–8 sessions spaced 4–8 weeks apart to intersect with follicle cycling across the treated area.

Misconception: Higher fluence always produces better results.
Correction: Exceeding the therapeutic window for a given tissue target and pulse duration causes nonselective thermal injury. The relationship between fluence and clinical outcome is not linear — it is bounded by the TRT of the target chromophore. Operating above this threshold destroys selectivity.

Misconception: Non-ablative lasers carry no risk of scarring.
Correction: Non-ablative modalities still deliver measurable thermal energy to dermis. Aggressive fluence settings, overlapping passes, or failure to account for tanned skin can produce thermal injury sufficient to cause scarring, particularly in phototypes IV–VI.

Misconception: Tattoo removal lasers erase ink immediately.
Correction: Laser pulses fragment ink particles into smaller particles that are subsequently phagocytized and cleared by the lymphatic system. This biological clearance process takes 6–8 weeks per session, which defines the minimum interval between treatments.

Misconception: All laser procedures are cosmetic and therefore not covered by insurance.
Correction: Certain laser procedures carry FDA clearances for medical indications. PDL treatment of port wine stains in pediatric patients, laser therapy for hemangiomas, and treatment of certain precancerous lesions may qualify for medical insurance coverage depending on payer policy and ICD-10 documentation. The skin conditions overview provides context on how diagnosis classification affects coverage determinations.

Checklist or steps (non-advisory)

The following sequence describes the standard procedural workflow for a dermatologic laser session as documented in peer-reviewed clinical literature and AAD guidelines. This is a descriptive reference, not clinical instruction.

Pre-procedure phase:
- [ ] Patient Fitzpatrick phototype documented and confirmed at consultation
- [ ] Relevant medications reviewed for photosensitizing agents (e.g., doxycycline, isotretinoin)
- [ ] Treatment area assessed for active tan, recent UV exposure, or inflammatory conditions
- [ ] Informed consent obtained detailing specific risks by wavelength and modality
- [ ] Test spot performed and evaluated at 4–6 weeks for ablative or pigment-targeting procedures (where applicable per protocol)
- [ ] Antiviral prophylaxis prescribed for ablative perioral resurfacing (herpes simplex virus reactivation risk)

Intra-procedure phase:
- [ ] Eye protection confirmed for patient and all personnel — ANSI Z136.3 laser safety eyewear matched to specific wavelength
- [ ] Room access controls enforced per ANSI Z136.1 standards (Laser Institute of America)
- [ ] Topical or injectable anesthesia administered where indicated
- [ ] Laser parameters (wavelength, pulse duration, fluence, spot size) documented before activation
- [ ] Treatment endpoint clinically evaluated (purpura for PDL, whitening/frosting for ablative, ash for Q-switched)

Post-procedure phase:
- [ ] Wound care instructions for ablative procedures documented
- [ ] Sun avoidance and SPF 30+ physical sunscreen initiated
- [ ] Follow-up interval scheduled per modality protocol
- [ ] Adverse event monitoring criteria explained (prolonged blistering, secondary infection signs, unexpected pigment change)

Reference table or matrix

Regulatory note: All devices listed require FDA 510(k) clearance or PMA for each specific indication. Unlabeled (off-label) use exists in clinical practice but lies outside FDA-cleared indications. State medical boards govern scope of practice — in most U.S. states, licensed physicians or physician-supervised personnel may operate laser devices, though specific delegation rules vary by jurisdiction.

References

- U.S. Food and Drug Administration — Center for Devices and Radiological Health (CDRH), 21 CFR Part 878

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)